Max Healthcare Institute Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 2,366.17 Cr (+16.70% YoY) and PAT growth of +4.87% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | August 13, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 2,366.17 Cr (+16.70% YoY) |
|---|
| PAT (Q1) | Rs. 322.96 Cr (+4.87% YoY) |
|---|
| EBITDA margin | 25.29% (-50 bps YoY) |
|---|
| EPS (Q1) | Rs. 3.32 (+4.73% YoY) |
|---|
| Market cap | Rs. 98,618.79 Cr |
|---|
| CMP | Rs. 1,013.30 |
|---|
Quarter Snapshot
Revenue grew 16.7% YoY with strong occupancy and CGHS tailwind, but EBITDA margin compressed 301 bps QoQ as doctor costs and new tower ramp-up costs outpaced growth. PAT rose only 4.87% due to cost escalation, higher depreciation/finance costs, and an elevated tax rate. The quarter is a building quarter with margin recovery expected as new beds fill and CGHS benefit annualises.
Key Investment Insights
Key Positives
- Revenue from operations grew 16.7% YoY to Rs.2,366.17 Cr, driven by CGHS rate revision, new bed additions, and Kalinga acquisition.
- Consolidated occupancy remained above 75%, indicating high asset utilisation.
- Subsidiary contribution to PAT grew 9.1% YoY to Rs.154.89 Cr, reflecting strong network performance.
- CGHS rate revision (full super-specialty rates) effective from April 1, 2026, is a structural tailwind.
- Bed count reached 6,100+ vs ~6,000 at end FY26, with pipeline to ~6,500 by FY27 end.
- Board approved Rs.425 Cr capex for Tower 3 at Vaishali, expanding bed capacity.
- Kalinga acquisition completed and integrated; YPPL Pune first tranche completed.
- CCI case closed with no adverse order (May 22, 2026).
Risk Factors
- EBITDA margin declined 301 bps QoQ (to 25.29%) and 50 bps YoY due to cost pressures and new tower costs not yet absorbed.
- Professional and consultancy fees (doctor costs) grew 22.76% YoY, outpacing revenue growth of 16.7%, pushing cost ratio to 22.12% of revenue.
- PAT growth of 4.87% YoY significantly lagged revenue growth of 16.7%, reflecting margin compression and higher tax rate.
- Effective tax rate increased to 25.98% from 23.09% YoY, a 290 bps headwind to PAT.
- Finance costs rose 29.44% YoY and depreciation 26.43% YoY due to capex and acquisition financing, pressuring bottom line.
- Standalone EBITDA declined 2.79% YoY, indicating weaker performance at the holding level compared to consolidated subsidiaries.